Cargando…
Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis
BACKGROUND: Therapeutic plasma exchange (TPE) is increasingly used throughout the world. Although the procedure itself is fairly standardized, it is yet unknown how the underlying disease entities influence the key coordinates of the treatment. METHODS: Retrospective chart review. The treatment indi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769505/ https://www.ncbi.nlm.nih.gov/pubmed/29334938 http://dx.doi.org/10.1186/s12882-017-0803-3 |
_version_ | 1783292907931828224 |
---|---|
author | Schmidt, Julius J. Asper, Firas Einecke, Gunilla Eden, Gabriele Hafer, Carsten Kielstein, Jan T. |
author_facet | Schmidt, Julius J. Asper, Firas Einecke, Gunilla Eden, Gabriele Hafer, Carsten Kielstein, Jan T. |
author_sort | Schmidt, Julius J. |
collection | PubMed |
description | BACKGROUND: Therapeutic plasma exchange (TPE) is increasingly used throughout the world. Although the procedure itself is fairly standardized, it is yet unknown how the underlying disease entities influence the key coordinates of the treatment. METHODS: Retrospective chart review. The treatment indications were clustered into four categories. Data are presented as median and interquartile (25–75%) range [IQR]. RESULTS: Within 1 year, 912 TPE treatments were performed in 185 patients (90 female, 48.6%). The distribution of the treatment numbers to the pre-specified disease categories were as follows: transplantation (35.7%), neurology (31.9%), vasculitis and immunological disease (17.3%), and others including thrombotic microangiopathy (8.1%), critical care related diseases (5.4%), hematology [multiple myeloma] (1.1%), and endocrine disorders (0.5%). The calculated plasma volume was significantly higher in patients with vasculitis and immunological diseases (3984 [3433–4439] ml) as compared to patients treated for transplant related indications (3194 [2545–3658] ml; p = 0.0003) and neurological diseases (3058 [2533–3359] ml; p < 0.0001). This was mainly due to the differences in the hematocrit which was 30.5 [27.0–33.6] % in the vasculitis/immunological disease patients and 40.2 [37.5–42.9] % in the neurological patients; p < 0.0001. Interestingly, treatment time using a membrane based technology was significantly longer than TPE using a centrifugal device 135.0 [125.0–140.0] min vs. 120.0 [112.5–135.0] min. Furthermore, the relative exchanged plasma volume was significantly lower in the treatment of vasculitis and immunological diseases as compared to treatments of transplant related indications and neurological diseases. CONCLUSION: Patients with low hematocrit and high body weight do not receive the minimum recommended dose of exchange volume. Centrifugal TPE allowed faster plasma exchange than membrane TPE. |
format | Online Article Text |
id | pubmed-5769505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-57695052018-01-25 Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis Schmidt, Julius J. Asper, Firas Einecke, Gunilla Eden, Gabriele Hafer, Carsten Kielstein, Jan T. BMC Nephrol Research Article BACKGROUND: Therapeutic plasma exchange (TPE) is increasingly used throughout the world. Although the procedure itself is fairly standardized, it is yet unknown how the underlying disease entities influence the key coordinates of the treatment. METHODS: Retrospective chart review. The treatment indications were clustered into four categories. Data are presented as median and interquartile (25–75%) range [IQR]. RESULTS: Within 1 year, 912 TPE treatments were performed in 185 patients (90 female, 48.6%). The distribution of the treatment numbers to the pre-specified disease categories were as follows: transplantation (35.7%), neurology (31.9%), vasculitis and immunological disease (17.3%), and others including thrombotic microangiopathy (8.1%), critical care related diseases (5.4%), hematology [multiple myeloma] (1.1%), and endocrine disorders (0.5%). The calculated plasma volume was significantly higher in patients with vasculitis and immunological diseases (3984 [3433–4439] ml) as compared to patients treated for transplant related indications (3194 [2545–3658] ml; p = 0.0003) and neurological diseases (3058 [2533–3359] ml; p < 0.0001). This was mainly due to the differences in the hematocrit which was 30.5 [27.0–33.6] % in the vasculitis/immunological disease patients and 40.2 [37.5–42.9] % in the neurological patients; p < 0.0001. Interestingly, treatment time using a membrane based technology was significantly longer than TPE using a centrifugal device 135.0 [125.0–140.0] min vs. 120.0 [112.5–135.0] min. Furthermore, the relative exchanged plasma volume was significantly lower in the treatment of vasculitis and immunological diseases as compared to treatments of transplant related indications and neurological diseases. CONCLUSION: Patients with low hematocrit and high body weight do not receive the minimum recommended dose of exchange volume. Centrifugal TPE allowed faster plasma exchange than membrane TPE. BioMed Central 2018-01-15 /pmc/articles/PMC5769505/ /pubmed/29334938 http://dx.doi.org/10.1186/s12882-017-0803-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Schmidt, Julius J. Asper, Firas Einecke, Gunilla Eden, Gabriele Hafer, Carsten Kielstein, Jan T. Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis |
title | Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis |
title_full | Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis |
title_fullStr | Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis |
title_full_unstemmed | Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis |
title_short | Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis |
title_sort | therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769505/ https://www.ncbi.nlm.nih.gov/pubmed/29334938 http://dx.doi.org/10.1186/s12882-017-0803-3 |
work_keys_str_mv | AT schmidtjuliusj therapeuticplasmaexchangeinatertiarycarecenter185patientsundergoing912treatmentsaoneyearretrospectiveanalysis AT asperfiras therapeuticplasmaexchangeinatertiarycarecenter185patientsundergoing912treatmentsaoneyearretrospectiveanalysis AT eineckegunilla therapeuticplasmaexchangeinatertiarycarecenter185patientsundergoing912treatmentsaoneyearretrospectiveanalysis AT edengabriele therapeuticplasmaexchangeinatertiarycarecenter185patientsundergoing912treatmentsaoneyearretrospectiveanalysis AT hafercarsten therapeuticplasmaexchangeinatertiarycarecenter185patientsundergoing912treatmentsaoneyearretrospectiveanalysis AT kielsteinjant therapeuticplasmaexchangeinatertiarycarecenter185patientsundergoing912treatmentsaoneyearretrospectiveanalysis |